Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 270

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 270
---
 out, our
operations have not been adversely affected by this situation, and we have not experienced disruptions to our development. However, the
intensity and duration of Israel’s current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war’s
economic implications on the Company’s business and operations and on Israel’s economy in general. The Company continues to
monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments impacting
its financial statements as appropriate.

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES |

| a. | Basis of presentation: |

The financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (the “U.S. GAAP”).

<div align='center'>F-23</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

| b. | Use of estimate in preparation of financial statements: |

The preparation of financial statements
in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in
the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates.

| c. | Financial statements in United States dollars: |

The functional and reporting currency
of the Company is the United States dollar (the “USD” or “U.S dollar”) as the U.S. dollar is the currency of the
primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.

The Company transactions and balances
denominated in U.S. dollars are presented at their original amounts. Non-U.S. dollar transactions and balances have been remeasured to
U.S. dollars in accordance with ASC 830, Foreign Currency Matters (“ASC 830”) of the Financial Accounting Standards
Board (the “FASB”). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in